CTLA4 and graft versus host disease: Since 2017, several new drugs have been FDA approved for second-line defense, i.e., ibrutinib, belumosudil, and ruxolitinib, and the CTLA-4 costimulation blocker abatacept is currently being examined for GVHD treatment (42–45).